MedTrace Logo

Breast Cancer Associated Antibodies

NCT00331942 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2007-03-02

No results posted yet for this study

Summary

To determine the ability of the Cimmunology process to lead to in vitro antibody production, the ability of the ELISA assays to detect any of those antibodies, and to establish the relationship between the ELISA results and the clinical / pathological status of the patient. The statistical significance of the CAAb test results will be determined.

Conditions

Sponsors & Collaborators

  • Lab Discoveries Ltd.

    lead INDUSTRY

Principal Investigators

  • Tamar J Cohen, Phd. · Lab Discoveries

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-07-31
Completion
2008-05-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00331942 on ClinicalTrials.gov